With second-quarter sales of over $232m in the US, Eli Lilly's Basaglar hybrid insulin glargine is close to becoming a $1bn blockbuster on a proforma annual basis. Global sales of the brand are already tracking well ahead of $1bn.
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
Already a subscriber?
Amgen told investors during its 1 May first-quarter earnings call that its Pavblu biosimilar to Eylea 2mg had flown out of the gates, while Regeneron admitted “some difficult news related to our retinal franchise.”
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
Despite industry-wide uncertainty surrounding the Trump administration’s interest in pharma-focused tariffs, Hikma has maintained its guidance for the 2025 financial year.
Samsung Bioepis has revealed first-quarter figures that reflect recent launches driving growth for the Korean biosimilars developer.
Generics Bulletin previews the most noteworthy and anticipated events for May 2025.
Sandoz has struck a deal worth up to $301m with Henlius giving it rights to a proposed ipilimumab biosimilar to Yervoy in countries across the world.
Reflecting increased regulatory pressure and a wider drive towards the reshoring of pharmaceutical manufacturing to the US, Speranza has launched a new generics business called Lotus Therapeutics.
